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ABSTRACT 
Aim: To study the pattern of cutaneous adverse drug reactions presenting to general practitioners in a 
semi urban area.   
Methodology and Results: This study was conducted among general practitioners of Villupuram, a 
semi urban area in Tamilnadu State. During the study, a total of 60 CADRs were reported. Data were 
collected using standard CDSCO ADR form. The majority of CADRs were observed in the age group of 20-
40 years. According to WHO causality assessment, 48 were probable and 12 were possible. The severity 
assessment using modified hartwig and seigel revealed 18 mild, 41 moderate and one severe CADRs. 
The common drug groups implicated are antibiotics followed by NSAIDS and anticonvulsants. 
Maculopapular rash was the most common presentation of CADRs.  
Conclusion: Among the various types of CADRs seen in this study, Maculopapular rash was the most 
common followed by fixed drug eruption. studies antimicrobials were the most common causative agent 
followed by NSAIDs and anti- convulsants. This study on CADRs gains importance as the pattern of drug 
use is changing periodically and everyday many new drugs enter the market. 
KEYWORDS: CDSCO ADR form causality assessment CADRs. 
INTRODUCTION
 Patient safety is an important parameter in 
health care systems. Worldwide adverse drug reactions 
are the major concerns in terms of patients safety and 
the quality of medical care. Adverse drug reactions are 
the major causes of hospital admission, increased 
expenditure, morbidity, and even death1. Drug use is 
always coupled with the risk of adverse reactions. Skin 
and mucosa are the common sites for initial presentation 
of many CADRs2. About 2-3% of hospitalized patients are 
affected by cutaneous ADRs due to variety of drugs3. 
 A CADRs is any undesirable change in the 
structure or function of the skin, its appendages or 
mucus membranes and it encompasses all adverse 
events related to drug eruption, regardless of etiology. 
Although cutaneous reactions are common, 
comprehensive information regarding their incidence, 
severity, and ultimate health effects in general practice 
are often not available as many cases go unreported4.  
 Drugs used for a long period of time may cause 
new types of skin eruptions that have not been observed 
previously5. It is estimated that only 50% of the 
undesirable reaction can be detected during the pre 
marketing clinical trials6. There is a wide spectrum of 
CADRs varying from transient maculopapular rash to 
fatal toxic epidermal necrolysis (TEN). The pattern of 
CADRs and the drugs responsible for them keep changing 
every year7. These reactions can arise as a result of 
immunologic (or) non immunologic mechanisms. The 
cessation of the offending agent along with the use of 
systemic and topical steroids and antihistamines may be 
helpful in the management. Proper data about the 
adverse effects of drugs help physicians to use drugs 
balancing the benefits and hazards8. 
 Early detection and treatment of CADRs along 
with identification of the causative agent, are essential 
for preventing the progression of the reaction, 
preventing additional exposures, and ensuring the 
appropriate use of medications9. A standardized 
approach is necessary to establish a final decision of 
causality to result in a consistent, accurate and 
reproducible identification of ADRs. It is most 
challenging and practically difficult when the patient is 
on multiple medicines10. To have knowledge of the 
CADRs prevailing in general practice of a semi urban area 
(Villupuram, Tamilnadu state), this study was designed 
with the following aim. 
AIM 
 To describe the pattern of cutaneous adverse 
drug reactions presenting to general practitioners in a 
semi urban area. 
OBJECTIVES 
(1) To describe the clinical presentation of cutaneous 
ADRs. 
(2) To identify the offending drugs and to associate 
causality and severity. 
MATERIALS AND METHODS 
 This study was conducted among general 
practitioners of Villupuram, a semi urban area in Tamil 
nadu state. All the patients who attended OPDS of 
general practitioners with suspected cutaneous ADRs 
were enrolled in the study. Daily and on-call visits to the 
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clinics were made to collect data. Drug history and data 
regarding all suspected cutaneous ADRs to drugs were 
collected after getting consent from the patient. Detailed 
data were collected using central drugs standard control 
organization (CDSCO) ADR from. Subjects who 
complained of only symptom (e.g. itching) without 
visible skin lesions and subjects whose lesions are 
disease related (viral exanthemas, rash of rickettsial 
infections etc) were excluded from the study. 
 The case causality assessment criteria 
recommended by the WHO Uppsala monitoring centre 
(WHO-UmC) was followed for assessing causality of 
individual reactions. Only certain, probable and possible 
were included for analysis. In order to assess the 
severity, Modified hartwig and siegel-1992 ADR severity 
assessment scale was used. 
Method of Statistical Analysis: Descriptive analysis.  
OBSERVATIONS AND RESULTS  
 A total of 60 cutaneous ADRs were reported 
during the study period. Among them 34 were males and 
26 were females. The youngest patient was of age 14 and 
oldest was of age 64. Majority of the patients were in the 
age group of 20-40 followed by 41-60 years. 
 The most common reaction pattern was 
maculopapular rash [30(50%)] followed by fixed drug 
eruption [10 (16%)], urticaria [8 (13%)], acneiform 
eruption [3 (5%)], erythema multiforme [3(5%)], 
photosensitivity drug rash [1(1.6%)], contact dermatitis 
[2 (3.2%)], angioedema [1 (1.6%)], and toxic epidermal 
necrolysis [1 (1.6%) ]. 
 The most common drug groups responsible for 
CADRs were antibiotics followed by NSAIDs/other 
analgesics and anticonvulsants. Antibiotics caused 20 
CADRs (33%), NSAIDs/other analgesics caused 14 
CADRs (23%), anticonvulsants 11 CADRs (18%) and 
other miscellaneous drugs caused remaining CADRs 
(25%). Beta lactams were the most common antibiotic 
causing CADRs followed by fluoroquinolones and sulpha 
groups of drugs. 
 Causality assessment was done using WHO 
causality assessment scale of suspected adverse drug 
reaction. Among 60 cases reported, 48were probable and 
12were possible. (Table-1). 
 The severities of the CADRs were assessed using 
modified Hartwig and Siegel ADR severity assessment 
scale 1992. Out of 60 cases 18 were mild, 41 cases were 
moderate and one was severe. 
Table1: WHO Causality assessment of Cutaneous 
adverse drug reactions 
Total number of cases 60 
probable 48 
possible 12 
Table 2: Commonly involved drug groups in 
cutaneous adverse drug reaction 
Drug Groups Reaction Type 
Antibiotics Maculopapular rash 
Fixed Drug Eruptions 
Toxic Epidermal Necrolysis 
Photosensitivity 
NSAIDS Maculopapular rash 
Fixed Drug Eruptions 
Urticaria 
Erythema multiforme 





Table 3: Severity assessment of CADRs (Modified 
Hartwig & Seigel-1992) 




Table 4: clinical pattern of CADRs 
Total Cases 60 
Maculopapular rash  30 
Fixed Drug Eruptions 10 
Urticaria 08 
Acneiform eruptions 03 
Erythema multiforme 03 
Photosensitivity 02 
Contact dermatitis 02 
Angioedema 01 
Toxic Epidermal Necrolysin 01 
DISCUSSION 
 This study was carried out with an objective of 
revealing the types of CADRs of the patients attending 
general practitioners in a semi urban area like 
Villupuram. Drug history is mandatory for the diagnosis. 
Polypharmacy is the main risk for CADRs in the study. 
We did not carry out rechallenge test during the study 
period. It has to be done with great caution and only if 
extremely necessary, because a rechallenge test may 
cause severe or even fatal reactions11. 
 In most of the cases, the suspected drug was 
withdrawn. In cases where the drugs were absolutely 
necessary and were not easily modified, the drugs were 
continued on supervision (eg) Anti tubercular drugs. 
Dermatologist opinion was obtained for serious CADRs 
like erythema multiforme and TEN and were closely 
monitored12. CADRs were common among men 
compared to women in our study13.Majority of the 
patients were in the age group of 20-40 in our trial and it 
is in accordance with other studies14. In some studies 
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elderly population was more susceptible to CADRs15. The 
difference in various studies may be due to the regional 
variation in the health care seeking behavior of the 
different population16. 
 Among the various types of CADRs seen in this 
study, Maculopapular rash was the most common 
followed by fixed drug eruption which is similar to some 
other studies17. In accordance to the earlier studies 
antimicrobials were the most common causative agent 
followed by NSAIDs and anti- convulsants 18. Among the 
antimicrobials, β lactams are the most common causative 
agent but in some studies fluoroquinolones cause more 
CADRs. These variations may be due to differences in 
prescription pattern of drug in different part of the 
world. 
CONCLUSION 
 In our study, a wide clinical spectrum of 
cutaneous ADRs ranging from mild maculopapular rash 
to serious TEN were observed. Antibiotics, NSAIDS and 
anti- convulsants were the most frequently implicated 
drug groups. This study on CADRs gains importance as 
the pattern of drug use is changing periodically and 
everyday many new drugs enter the market. The patients 
diagnosed with CADRs were informed about the 
suspected drugs and the chances of cross reactivity with 
related groups. 
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